biotech investing argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
biotech investing argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
biotech investing argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
biotech investing argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
biotech investing argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
biotech investing argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
biotech investing argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
biotech investing argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada
Questcorp Mining and Riverside Resources Report High-Grade Gold, Silver and Base Metal Results and Advance Toward Fully Funded Phase 2 Drill Program at La Union, Sonora
Alvopetro Announces April Sales Volumes, Quarterly Natural Gas Pricing Update and Details for Q1 2026 Earnings Call
